Lee Jeeyun, Suh Cheolwon, Huh Jooryung, Jun Hyun Jung, Kim Kihyun, Jung Chulwon, Park Keunchil, Park Yeon Hee, Ko Young Hyeh, Kim Won Seog
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Clin Cancer Res. 2007 Jun 1;13(11):3250-4. doi: 10.1158/1078-0432.CCR-06-2373.
The aim of the study was to determine the effect of EBV-encoded RNA-1 in situ hybridization (EBER-1 ISH) in bone marrow specimens on survival outcome in patients with clinical stage I/II natural killer/T-cell lymphoma.
We systematically did EBER-1 ISH on 182 archival bone marrow tissues from 91 patients who were diagnosed of stage I/II natural killer/T-cell lymphoma and analyzed the correlation between bone marrow EBER-1 ISH status and survival. We defined minimal bone marrow involvement and definite bone marrow involvement to distinguish the subgroups who revealed EBV-positive cells from normal marrow by EBER-1 ISH from those who showed typical neoplastic cells in bone marrow biopsies.
In total, 17 of the 91 (18.7%) patients showed positivity for EBER-1 ISH at least in one of the bilateral bone marrow biopsies with 14 minimal bone marrow involvements and 3 definite bone marrow involvements. Patients with positive bone marrow EBER-1 ISH showed significantly poorer overall survival than those who were negative for bone marrow EBER-1 ISH (median survival, 16.1 months versus not reached; P = 0.045).
Considering a high proportion of stage I/II patients (15.4%) with minimal in bone marrow specimens, bone marrow EBER-1 ISH should be routinely done in all patients with localized disease for more accurate staging.
本研究旨在确定骨髓标本中EB病毒编码的RNA-1原位杂交(EBER-1 ISH)对临床I/II期自然杀伤/T细胞淋巴瘤患者生存结局的影响。
我们对91例诊断为I/II期自然杀伤/T细胞淋巴瘤患者的182份存档骨髓组织系统地进行了EBER-1 ISH检测,并分析了骨髓EBER-1 ISH状态与生存之间的相关性。我们定义了最小骨髓受累和明确骨髓受累,以区分通过EBER-1 ISH在骨髓活检中显示EBV阳性细胞的亚组与显示典型肿瘤细胞的亚组。
总共91例患者中有17例(18.7%)至少在双侧骨髓活检中的一份中显示EBER-1 ISH阳性,其中14例为最小骨髓受累,3例为明确骨髓受累。骨髓EBER-1 ISH阳性的患者总生存期明显低于骨髓EBER-1 ISH阴性的患者(中位生存期分别为16.1个月和未达到;P = 0.045)。
考虑到I/II期患者中有较高比例(15.4%)在骨髓标本中存在最小受累,对于所有局限性疾病患者,应常规进行骨髓EBER-1 ISH检测以进行更准确的分期。